The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

“While GLP-1-based therapies have revolutionized patient care for obesity and Type 2 diabetes ... two holy grails in this ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

GUBamy is part of the investigational amylin field, a burgeoning landscape that includes Novo Nordisk’s CagriSema, a ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Wegovy: Novo Nordisk’s name-brand version of injectable semaglutide to help adults and children 12 years and older with ...